Anova Enterprises Reaches 500 Urology Research Sites in Digital Clinical Trial Network
核心洞察
Anova Enterprises (搜索) has expanded its virtual urology research network to 500 active clinical sites, creating the largest digitally connected ecosystem for urology research.
The AnovaOS (搜索) platform enables rapid site-to-study matching, streamlined study start-up, and faster patient enrollment across diverse urology practices.
The network addresses longstanding challenges in urology research including fragmented infrastructure and inconsistent patient recruitment by connecting community urologists, academic centers, and multi-specialty hospital groups.
Anova Enterprises (搜索), Inc., a technology-enabled Clinical Research Organization (CRO), has achieved a significant milestone by expanding its virtual urology research network to 500 active clinical sites through its proprietary AnovaOS (搜索) platform. This achievement establishes the largest digitally connected ecosystem for urology research, addressing critical infrastructure challenges that have historically limited clinical trial efficiency in the field.
Addressing Urology Research Challenges
The virtual urology research network was specifically designed to tackle longstanding obstacles in urology clinical trials, including fragmented site infrastructure, inconsistent patient recruitment, and lengthy trial activation timelines. By digitally connecting community urologists, academic centers with urology programs, and multi-specialty hospital groups into a unified research ecosystem, the platform standardizes performance and reduces operational burden while enabling rapid activation for industry-sponsored studies.
"Reaching our 500th urology site underscores the need for a modern, connected approach to the conduct of urology research," said Martin Walsh, President and Co-founder of Anova. "AnovaOS (搜索) has transformed how sites and sponsors collaborate on complex clinical trials by giving them the digital tools, operational support, and real-time insights needed to run studies efficiently and with high quality."
Technology Platform Capabilities
The AnovaOS (搜索) platform provides integrated capabilities including digital feasibility assessment, automated start-up processes, patient-matching algorithms, remote monitoring, and comprehensive document and data management. The system also features adverse event and medical monitoring capabilities, all designed to reduce administrative effort and improve the speed and quality of data collection.
Key features of the virtual urology research network include centralized study coordination for consistent quality and faster activation, accelerated enrollment supported by AI-enabled patient identification and digital engagement tools, and improved study oversight through real-time dashboards and automated compliance monitoring.
Expanding Patient Access
Chris Beardmore, CEO and Co-founder of Anova, highlighted the importance of broadening research access beyond traditional academic medical centers. "Urology research has traditionally organized around a small number of academic medical centers. Because patients with urologic conditions are often treated at community practices and hospitals, this limits patient access, increases cost and slows innovation," Beardmore explained. "Our virtual network brings promising new treatments to where patients receive care. This milestone reflects our commitment to making trials more inclusive, efficient, and impactful."
Network Performance and Future Plans
The effectiveness of the AnovaOS (搜索) urology research network has been demonstrated through multiple clinical trials and compassionate use programs previously announced by Anova. The network adds to Anova's comprehensive global just-in-time network, which includes oncology, immunology, cardiology, infectious disease, and neurology practices engaged with the AnovaOS platform.
With the 500th urology site now active, Anova plans continued site expansion across North America, Europe, and Asia-Pacific regions. The company also intends to launch disease-specific sub-networks focusing on areas such as prostate cancer (搜索), bladder cancer (搜索), and benign prostatic hyperplasia (搜索) (BPH). Additionally, Anova plans to deliver innovative and adaptive study designs with industry partners following the American Urology Association meeting scheduled for May 2026 in Washington, D.C.